These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9632021)

  • 21. A betamethasone-calcipotriene combination for psoriasis.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):55-6. PubMed ID: 16841023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
    Hashim PW; Nia JK; Terrano D; Goldenberg G; Kircik LH
    J Drugs Dermatol; 2017 Aug; 16(8):747-752. PubMed ID: 28809989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in topical sequential therapy for psoriasis.
    Koo JY
    Skin Therapy Lett; 2005 Nov; 10(9):1-4. PubMed ID: 16292458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UVB blocking effect of calcipotriene ointment 0.005%.
    Marsico RE; Dijkstra JW
    J Am Acad Dermatol; 1996 Mar; 34(3):539-40. PubMed ID: 8609280
    [No Abstract]   [Full Text] [Related]  

  • 25. Calcipotriene 0.005% and betamethasone dipropionate 0.064% combination topical suspension (Taclonex Scalp).
    Scheinfeld NS
    Skinmed; 2011; 9(3):179-80. PubMed ID: 21675498
    [No Abstract]   [Full Text] [Related]  

  • 26. Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
    Frieder J; Kivelevitch D; Menter A
    Ther Deliv; 2017 Aug; 8(9):737-746. PubMed ID: 28659016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
    Tirado-Sánchez A; Ponce-Olivera RM
    Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
    Kin KC; Hill D; Feldman SR
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
    Highton A; Quell J
    J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
    Coynik D
    Cutis; 2000 Dec; 66(6 Suppl):19-24. PubMed ID: 11147087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once daily vs. twice daily applications of topical treatments in psoriasis.
    van de Kerkhof PC
    Br J Dermatol; 2005 Dec; 153(6):1245. PubMed ID: 16307677
    [No Abstract]   [Full Text] [Related]  

  • 32. Per-gram cost of medication is by itself a poor indicator for comparing costs of different psoriasis treatments: a retrospective cohort study of the cost of psoriasis treatment with topical corticosteroids versus topical calcipotriene.
    Feldman SR; Sahu S; Fleischer AB; Dezii CM
    J Cutan Med Surg; 2000 Jul; 4(3):121-5. PubMed ID: 11003715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.
    Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Grover's disease successfully treated with calcipotriene/betamethasone dipropionate ointment.
    Takahagi S; Ashizawa S; Tanaka A; Hide M
    Dermatol Ther; 2020 Nov; 33(6):e14217. PubMed ID: 32820850
    [No Abstract]   [Full Text] [Related]  

  • 36. Vitamin D and psoralen plus UVA radiation.
    Mascaró JM
    Cutis; 2002 Nov; 70(5 Suppl):13-5. PubMed ID: 12467334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating psoriasis with calcipotriol.
    Newbold PC
    BMJ; 1992 Oct; 305(6858):847-8. PubMed ID: 1422394
    [No Abstract]   [Full Text] [Related]  

  • 38. Generalized pustular psoriasis precipitated by topical calcipotriol ointment.
    Tamiya H; Fukai K; Moriwaki K; Ishii M
    Int J Dermatol; 2005 Sep; 44(9):791-2. PubMed ID: 16135156
    [No Abstract]   [Full Text] [Related]  

  • 39. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generalised pustular psoriasis: response to topical calcipotriol.
    Berth-Jones J; Bourke J; Bailey K; Graham-Brown RA; Hutchinson PE
    BMJ; 1992 Oct; 305(6858):868-9. PubMed ID: 1422400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.